Redwood City, CA – Oct 03, 2012 – Ingenuity® Systems, a leading provider of biomedical information and analysis solutions, today announced a partnership with Life Technologies Corporation to develop and deliver a joint solution for rapid, high-confidence interpretation of molecular profiling information from Life Technologies’ diagnostic tests.
Ingenuity Systems’ unique software and content will be provided to interpreting physicians, such as molecular pathologists and medical geneticists, in a dedicated portal for the interpretation of Life’s molecular diagnostic test kits. Users of this interpretation portal will be able to review disease management guidelines, identify clinical trials, and find cutting- edge insights from biomedical research. The Ingenuity Systems solution will be made available in context with other software and database solutions, to provide a wide range of information that may help physicians to find suitable treatment options or clinical trials for patients. Through these tools, interpreting physicians will leverage the comprehensive, expert-curated Ingenuity Knowledge Base of biomedical content, including an up-to-date database of all human disease phenotype associated variants.
Results of the interpretation process will then be conveyed through a reporting portal to treating physicians. While these tools will not provide medical decisions to treating physicians, they will provide contextual information that may identify treatment options based on biological factors of a patient’s disease. Consistent with Life Technologies’ recent launch of a test for lung cancer risk stratification, the solution will initially be made available for Life Technologies’ emerging line of cancer diagnostic tests.
“Advanced diagnostic tests like the ones we are developing at Life Technologies will deliver increasingly complex information about a patient’s disease,” said Ronnie Andrews, president of Life Technologies’ Medical Sciences division. “It is essential that those results be made relevant to interpreting physicians by making all possible contextual information available in a single interpretation portal. We believe that Ingenuity Systems provides unique and valuable information, and we are pleased to work with them to shape the repertoire of information that the physicians interpreting our tests can employ to understand the biology of their patient’s disease.”
“With its broad technology platforms and targeted acquisitions Life Technologies is rapidly emerging as a leading provider of clinical diagnostic solutions,” said Jake Leschly, CEO of Ingenuity System. “Our unique content and applications address a critical bottleneck in the development of the clinical diagnostic market and our partnership with Life enables a unique and powerful end-to-end solution for the molecular pathologist.”
About Ingenuity® Systems
Ingenuity® Systems is a leading provider of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems in life science research and molecular diagnostics. Today, Ingenuity’s solutions are used by tens of thousands of researchers and clinicians at hundreds of leading pharmaceutical, biotechnology, academic, diagnostic and clinical institutions worldwide.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Director of Marketing